

Pilar Rivera-Ortega

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6205080/pilar-rivera-ortega-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

1,658
citations

9
h-index

39
g-index

39
ext. papers

2,938
ext. citations

12.8
avg, IF

3.9
L-index

#	Paper	IF	Citations
20	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2030-2040	59.2	628
19	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 1637-1645	40	537
18	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 2049-2059	40	157
17	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 605-612	40	117
16	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1656-1665	10.2	72
15	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 1275-1287	35.1	58
14	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018 , 12, 1753466618800618	4.9	27
13	The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. <i>ERJ Open Research</i> , 2019 , 5,	3.5	24
12	Interstitial Lung Diseases in Developing Countries. <i>Annals of Global Health</i> , 2019 , 85,	3.3	10
11	Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers. <i>Respirology</i> , 2021 , 26, 352-359	3.6	8
10	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	6
9	Trabecular bone score in active or former smokers with and without COPD. <i>PLoS ONE</i> , 2019 , 14, e0209737	3.7	3
8	Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.		3
7	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. <i>Advances in Therapy</i> , 2021 , 38, 4505-4519	4.1	3
6	Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention. <i>Panminerva Medica</i> , 2021 , 63, 110-121	2	2
5	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 231-233	1.1	1
4	Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity. <i>Archivos De Bronconeumologia</i> , 2021 , 58, 135-135	0.7	1

3	Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD. <i>International Journal of COPD</i> , 2020 , 15, 1823-1829	3	0
2	An update on interstitial lung disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021 , 82, 1-14	0.8	0
1	Reply to Althuwaybi : Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 522-524	10.2	